Cubist Systematic Strategies, LLC Achilles Therapeutics PLC Transaction History

Cubist Systematic Strategies, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$2.26 - $3.38 $903 - $1,352	400 Added 58.39%	1,085 $2,000
Q2 2022 Aug 15, 2022	BUY	$1.96 - $3.04 $196 - $304	100 Added 17.09%	685 $2,000
Q1 2022 May 16, 2022	SELL	$2.8 - $5.23 $1,190 - $2,222	-425 Reduced 42.08%	585 $2,000
Q4 2021 Feb 14, 2022	SELL	$4.22 - $8.86 $3,692 - $7,752	-875 Reduced 46.42%	1,010 $5,000
Q3 2021 Nov 15, 2021	BUY	$5.81 - $9.93 $10,951 - $18,718	1,885 New	1,885 $15,000

24.3M

Ticker ACHL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,774,000
Market Cap $47.3M
Description
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.